The Metabolic Syndrome - from Insulin Resistance to Obesity and Diabetes

被引：73

作者：

Gallagher, Emily Jane ^{[3
]}

LeRoith, Derek ^{[3
]}

Karnieli, Eddy ^{[1
,2
]}

机构：

[1] Technion Israel Inst Technol, Rambam Med Ctr, Inst Endocrinol Diabet & Metab, IL-31096 Haifa, Israel

[2] Technion Israel Inst Technol, RB Rapaport Fac Med, IL-31096 Haifa, Israel

[3] Mt Sinai Med Ctr, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2008年 / 37卷 / 03期

关键词：

D O I：

10.1016/j.ecl.2008.05.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In today's society with the escalating levels of obesity, diabetes, and cardiovascular disease, the metabolic syndrome is receiving considerable attention and is the subject of much controversy. Greater insight into the mechanism(s) behind the syndrome may improve our understanding of how to prevent and best manage this complex condition.

引用

页码：559 / +

页数：22

共 117 条

[11] Peroxisome proliferator-activated receptor-γ represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect [J].

Armoni, M ;

Kritz, N ;

Harel, C ;

Bar-Yoseph, F ;

Chen, H ;

Quon, MJ ;

Karnieli, E .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (33) :30614-30623

[12] Transcriptional regulation of the GLUT4 gene:: from PPAR-γ and FOXO1 to FFA and inflammation [J].

Armoni, Michal ;

Harel, Chava ;

Karnieli, Eddy .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2007, 18 (03) :100-107

[13] FOXO1 represses peroxisome proliferator-activated receptor-γ1 and -γ2 gene promoters in primary adipocytes -: A novel paradigm to increase insulin sensitivity [J].

Armoni, Michal ;

Harel, Chava ;

Karni, Shiri ;

Chen, Hui ;

Bar-Yoseph, Fabiana ;

Ver, Marel R. ;

Quon, Michael J. ;

Karnieli, Eddy .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (29) :19881-19891

[14] Harmonizing the definition of the metabolic syndrome: Comparison of the Criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations [J].

Assmann, Gerd ;

Guerra, Rudy ;

Fox, Garrett ;

Cullen, Paul ;

Schulte, Helmut ;

Willett, DuWayne ;

Grundy, Scott M. .

AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (04) :541-548

[15] The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions [J].

Athyros, VG ;

Ganotakis, ES ;

Elisaf, M ;

Mikhailidis, DP .

CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (08) :1157-1159

[16]

Balkau B, 1999, DIABETIC MED, V16, P442

[17] Statin safety and drug interactions: Clinical implications [J].

Bottorff, MB .

AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :27C-31C

[18] Body mass index and the prevalence of hypertension and dyslipidemia [J].

Brown, CD ;

Higgins, M ;

Donato, KA ;

Rohde, FC ;

Garrison, R ;

Obarzanek, E ;

Ernst, ND ;

Horan, M .

OBESITY RESEARCH, 2000, 8 (09) :605-619

[19] The metabolic syndrome: prevalence in worldwide populations [J].

Cameron, AJ ;

Shaw, JE ;

Zimmet, PZ .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2004, 33 (02) :351-+

[20] Metabolic and therapeutic lessons from genetic manipulation of GLUT4 [J].

Charron, MJ ;

Katz, EB .

MOLECULAR AND CELLULAR BIOCHEMISTRY, 1998, 182 (1-2) :143-152

← 1 2 3 4 5 6 7 8 9 10 →